Pfizer completes the acquisition of InnoPharma for USD 360 million

Source: Biovalley 2014-9-26 Pfizer recently announced that it has completed the acquisition of innopharma, a private pharmaceutical R & D company The acquisition cost US $360 million, including a cash sum of US $225 million and a phased payment of US $135 million The acquisition will help build a strong sterile injection line in areas such as cancer and central nervous system Innopharma is experienced in the development of difficult, differentiated and sterile injectable products Previously, John young, President of Pfizer's global mature pharmaceutical business, said: "at present, we are continuously exploring innovative growth opportunities in sterile injection product portfolio, and the acquisition of innopharma is an important milestone Innopharma's technical capabilities in bringing complex generic drugs to the market, as well as its competitive talents and product lines, will strengthen our ability to develop and promote important drugs that patients need urgently " Pfizer's injectable drugs are part of its global mature drug business, including the manufacture, production and sale of human drugs and surgical products The existing sterile injectable product portfolio on sale already includes 44 products, covering more than 190 injection points in the United States Innopharma's existing product portfolio includes 10 generic drugs approved by the U.S Food and Drug Administration (FDA), 19 products submitted to the FDA, and more than 30 injectable and ophthalmic products under development The company is committed to developing new formulations of existing drugs, including various products with production difficulties, such as the complex production capacity required, or products with challenges in bioequivalence, such as cancer and central nervous system disorders Innopharma was founded in 2005 and has a comprehensive R & D facility in Piscataway, New Jersey The company has developed the development ability of complex injectable products, including injection pen, slow-release injection, etc Efforts are being made to extend this expertise to new formulations such as oral suspensions and nasal preparations.